NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal [Committee B] meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 26 March, from 10am to 5:15pm

**Location:** 10 Spring Gardens London SW1A 2BU

# Committee members present

1. Dr Amanda Adler [Chair] Present for all items
2. Dr Sanjeev Patel Present for all items
3. Dr Carlo Berti Present for all items
4. Professor John Cairns Present for all items
5. Mr Mark Chapman Present for all items
6. Mr Diar Fattah Present for items 1 to 3.2.2
7. Ms Susan Faulds Present for all items
8. Mr Richard Hoddes Present for all items
9. Mr Gareth Hooper Present for all items
10. Dr Sanjay Kinra Present for all items
11. Dr Nicholas Latimer Present for all items
12. Mr Christopher O’Regan Present for all items
13. Professor Stephen Palmer Present for all items
14. Professor Allyson Pollock Present for items 1 to 3.2.2
15. Dr Stephen Smith Present for all items
16. Mr William Turner Present for all items
17. Professor Nicky Welton Present for all items
18. Mr Nigel Westwood Present for all items
19. Dr Stuary Williams Present for all items
20. Mr Tony Wootton Present for all items

# NICE staff present:

Helen Knight, Programme Present for all items

director

Nicole Elliott, Associate Present for all items

director

Jeremy Powell, Project Present for all items

manager

Sandra Aleknavice, Administrator Present for all items

Bashama Anjum, Administrator Present for items 1 to 3.2

Sharlene Ting, Technical Present for items 1 to 3.2.2

analyst

Ross Dent, Technical Present for items 1 to 3.2.2

advisor

Alan Lamb, Technical analyst Present for items 4 to 4.2.2

Rebecca Albrow, Technical Present for items 4 to 5

analyst

Thomas Walker, Technical Present for items 4 to 5

adviser

Helen Barnett, Medical editor Present for all items

Dalia Dawoud, Technical Present for items 1 to 3.2.2

analyst

Eleanor Donegan, Technical Present for items 1 to 3.2.2

adviser

Edgar Masanga, Business Present for all items

analyst

Irina Voicechovskaja, Technical Present for items 1 to 3.2.2

Adviser

Alan Thomas, New member of Present for items 1 to 3.2.1

the NICE technical appraisals appeal

committee

# External group representatives present:

Lena Al-Khudairy Senior Present for items 1 to 3.1.2

research fellow, Warwick evidence

Felix Achana, Senior research Present for items 1 to 3.1.2

fellow, Warwick evidence

Professor Aileen Clarke, Present for items 1 to 3.1.2

Professor of public health &

health services, Warwick evidence

# Clinical & patient experts present:

Dr Parth Narendran, Reader in Present for items 3 to 3.1.2

diabetes medicine, and honorary

consultant, University of Birmingham,

clinical expert - nominated by AstraZeneca

Professor John Petrie, Professor Present for items 3 to 3.1.2

of diabetic medicine, university of

Glasgow, clinical expert – nominated by

AstraZeneca

Rachael Crisp, Senior policy and Present for items 3 to 3.1.2

public affairs officer, JRDF, patient

expert – nominated by JRDF

Dr Kieran McCafferty, Consultant Present for items 4 to 4.1.3

nephrologist, Barts health NHS trust,

clinical expert – nominated by AstraZeneca

Professor Giuseppe Rosano, Present for items 4 to 4.1.3

professor and consultant cardiologist

st george’s hospitals NHS trust,

clinical expert – nominated by AstraZeneca

Mr Nick Hartstone Evans, patient Present for items 4 to 4.1.3

expert nominated by the pumping

wonderful organisation

Mrs Fiona Loud, patient expert Present for items 4 to 4.1.3

nominated by kidney care UK

# Observers present:

Professor Matthew Stevens, Present for items 4 to 4.1.3

professor of health technology

assessment

Dr Lesley Uttley, Research fellow Present for items 4 to 4.1.3

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. Appraisal of dapagliflozin for type 1 diabetes [ID1478]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from insert company name.
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Mr Gareth Hooper, Dr Sanjay Kinra, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Stephen Palmer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of dapagliflozin for type 1 diabetes [ID1478].
* Dr Parth Narendran declared a personal specific financial interest as he has participated in advisory board meetings for AstraZeneca, Abbott and Roche. Dr Narendran also declared that he has received speaker fees from AstraZeneca, Eli Lilly and Novartis and contributions to conference attendance from Eli Lilly.  
   - It was decided that this declaration would not prevent Dr   
   Narendran from participating in this section of the meeting
* Professor John Petrie declared a personal specific financial interest as he has received fees from AstraZeneca for attending an adivsory board on dapagliflozin. Professor Petrie also declared that he had undertaken endpoint committee work for contract research organisations and is an investigator of a trial of empagliflozin. He is also taking part in a JRDF funder trial to which AstraZeneca have agreed to donate dapagliflozin and placebo.  
   - It was decided that this declaration would not prevent Professor   
   Petrie from participating in this section of the meeting
* The Chair introduced the lead team, Dr Nicholas Latimer and Mr Nigel Westwood who, together with the Chair, gave presentations on the clinical effectiveness and cost effectiveness of dapagliflozin for type 1 diabetes [ID1478]
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD]. The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.

1. Appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from AstraZeneca
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Mr Gareth Hooper, Dr Sanjay Kinra, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Stephen Palmer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
* Dr Kieran McCafferty declared a personal non specific financial interest as he has participated in advisory boards and given talks on behalf of Vifor. Dr McCafferty is also named on a grant from AstraZeneca to support a clinical study (in a field not related to potassium binders).  
   - It was agreed that this declaration would not prevent Dr McCafferty from participating in this part of the meeting.

No further conflicts of interest were declared for this item.

* + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD].

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee B) will be held on Thursday 30 May 2019 and will start promptly at 10am.